Avalon Pharmaceuticals Announces Its Proprietary Drug Discovery and Development Platform AvalonRx(R) Identifies Potent Selective Inhibitors for the c-Myc and Beta-catenin Pathways.GERMANTOWN, Md. -- Avalon Pharmaceuticals, Inc. (Nasdaq:AVRX), today announced its proprietary drug discovery and development platform, AvalonRx([R]), identified potent selective inhibitors for the c-Myc and Beta-catenin pathways. The results will be presented today at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in San Francisco San Francisco (săn frănsĭs`kō), city (1990 pop. 723,959), coextensive with San Francisco co., W Calif., on the tip of a peninsula between the Pacific Ocean and San Francisco Bay, which are connected by the strait known as the Golden , CA from 12:30pm-2:30pm and from 5:30pm-7:30pm (PDT PDT abbr. Pacific Daylight Time PDT Pacific Daylight Time PDT n abbr (US) (= Pacific Daylight Time) → hora de verano del Pacífico PDT ) in posters titled: "A biomarker based high throughput screen identifies small molecular weight modulators of the Beta-catenin pathway;" "Biomarker based high-throughput screening High-throughput screening (HTS), is a method for scientific experimentation especially used in drug discovery and relevant to the fields of biology and chemistry. Purpose and method for identification of small molecule inhibitors, targeting the antiproliferative property of the c-Myc signaling pathway." "The unique capabilities of AvalonRx[R] allow us to target two of the most important, but historically "undruggable" cancer pathways, namely Myc and Beta-catenin," stated Stephen Horrigan, Ph.D., Vice President of Research. "These programs should result in the development of true "first-in-class" therapeutics with direct relevance to human disease." AvalonRx([R]) AvalonRx([R]) is a comprehensive, innovative and proprietary suite of technologies based upon large-scale gene expression analysis. This platform facilitates drug discovery by expanding the range of therapeutic targets for drug intervention, including targets and target pathways frequently considered intractable using conventional HTS HTS Heights HTS Harmonized Tariff System HTS High Throughput Screening (biomolecular assay screening) HTS High-Throughput Screening (Pharmaceutical Industry) HTS Harmonized Tariff Schedule approaches, allows more informed decisions about which compounds to advance towards clinical trials, and facilitates drug development through identification of biomarkers of efficacy that can stratify strat·i·fy v. strat·i·fied, strat·i·fy·ing, strat·i·fies v.tr. 1. To form, arrange, or deposit in layers. 2. patients or provide early indicators of response. About Avalon Pharmaceuticals Avalon is a biopharmaceutical company focused on the discovery, development and commercialization of first-in-class cancer therapeutics. Avalon's lead product candidate, AVN AVN Aviation AVN Avenue AVN Adult Video News AVN Avascular Necrosis AVN Atrioventricular Node AVN Aviation Model (weather forecast model, now Global Forecast System) AVN Air Vanuatu (ICAO code) 944, an IMPDH inhibitor, is in Phase II clinical development. Avalon also has preclinical programs to develop inhibitors of the Beta-catenin and Aurora/Centrosome pathways, discovery programs for inhibitors of the Survivin and Myc pathways and partnerships with Merck, MedImmune, ChemDiv, Medarex, and Novartis. AvalonRx([R]) is the company's proprietary platform which is based on large-scale biomarker identification and monitoring, used to discover and develop therapeutics for pathways that have historically been characterized as "undruggable." Avalon is headquartered in Germantown, MD. Safe Harbor Safe Harbor 1. A legal provision to reduce or eliminate liability as long as good faith is demonstrated. 2. A form of shark repellent implemented by a target company acquiring a business that is so poorly regulated that the target itself is less attractive. Statement This announcement contains, in addition to historical information, certain forward-looking statements forward-looking statement A projected financial statement based on management expectations. A forward-looking statement involves risks with regard to the accuracy of assumptions underlying the projections. that involve risks and uncertainties. Such statements reflect the current views of Avalon management and are based on certain assumptions. Actual results could differ materially from those currently anticipated as a result of a number of factors, risks and uncertainties, including those specified under the "Risk Factors" section of our 2006 Annual Report on Form 10-K Form 10-K A report required by the SEC from exchange-listed companies that provides for annual disclosure of certain financial information. Form 10-K See 10-K. and updates contained in subsequent filings we make with the Securities and Exchange Commission. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion